Improvement in prognosis of dilated cardiomyopathy in the elderly over the past 20 years

Journal of Cardiology

Volumn 52, Issue 2, 2008, Pages 111-117

  Kubo, Toru ^a   Matsumura, Yoshihisa ^a   Kitaoka, Hiroaki ^a   Okawa, Makoto ^a   Hirota, Takayoshi ^a   Hamada, Tomoyuki ^a   Hitomi, Nobuhiko ^a   Hoshikawa, Eri ^a   Hayato, Kayo ^a   Shimizu, Yuji ^a   Yamasaki, Naohito ^a   Yabe, Toshikazu ^a   Nishinaga, Masanori ^a   Takata, Jun ^a   Doi, Yoshinori ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Cardiomyopathies; Dilated; Elderly; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

AGED; AGING; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HEART VENTRICLE TACHYCARDIA; HEART VENTRICULOGRAPHY; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOMYOPATHY, DILATED; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; PROGNOSIS; VENTRICULAR FIBRILLATION;

EID: 52049089968     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2008.06.001     Document Type: Article

References (25)

1. Report of the 1995 World Health Organization/International Society and Federation of cardiology task force on the definition and classification of cardiomyopathy. Circulation 1996;93:841-42.
2. Dec G.W., and Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 331 (1995) 1564-1575
3. Fuster V., Gersh B.J., Giuliani E.R., Tajik A.J., Brandenburg R.O., and Frye R.L. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 47 (1981) 525-531
4. Ogasawara S., Sekiguchi M., Hiroe M., Komazawa T., Kawai Y., Fujita N., et al. Prognosis of dilated cardiomyopathy: from a retrospective to a prospective study employing multivariate analysis. Jpn Circ J 51 (1987) 699-706
5. Diaz R.A., Obasohan A., and Oakley C.M. Prediction of outcome in dilated cardiomyopathy. Br Heart J 58 (1987) 393-399
6. Doi Y.L., Chikamori T., Takata J., Yonezawa Y., Poloniecki J.D., Ozawa T., et al. Prognostic value of thallium-201 perfusion defects in idiopathic dilated cardiomyopahty. Am J Cardiol 67 (1991) 188-193
7. Komajda M., Jais J.P., Reeves F., Goldfarb B., Bouhour J.B., Juillieres Y., et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 11 (1990) 824-831
8. Manolio T.A., Baughman K.L., Rodeheffer R., Pearson T.A., Bristow J.D., Michels V.V., et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol 69 (1992) 1458-1466
9. Matsumura Y., Takata J., Kitaoka H., Kubo T., Baba Y., Hoshikawa E., et al. Long-term prognosis of dilated cardiomyopathy revisited-an improvement in survival over the past 20 years. Circ J 70 (2006) 376-383
10. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
11. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study-ELITE II. Lancet 355 (2000) 1582-1587
12. Cohn J.N., and Tognoni G. Valsartan heart failure trial investigators: a randomized trial of the angiotensin-receptor blocker valsasrtan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
13. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., et al. CHARM investigators and committees: effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362 (2003) 772-776
14. Packer M., et al., US Carvedilol Heart Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
15. CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 353 (1999) 2001-2007
16. Tsuchihashi M., Tsutsui H., Kodama K., Kasagi F., and Takeshita A. Clinical characteristics and prognosis of hospitalized patients with congestive heart failure-a study in Fukuoka. Jpn Circ J 64 (2000) 953-995
17. Ho K.K., Pinsky J.L., Kannel W.B., and Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22 (1993) 6A-13A
18. Massie B.M., and Shah N.B. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 133 (1997) 703-712
19. Matsumori A., Furukawa Y., Hasegawa K., Sato Y., Nakagawa H., Morikawa Y., et al. Epidemiologic and clinical characteristics of cardiomyopathies in Japan-results from nationwide surveys. Circ J 66 (2002) 323-336
20. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
21. Epstein A.E., Bigger J.T., Wyse D.G., Romhilt D.W., and Reynolds-Haertle R.A. Hallstrom AP and the CAST investigators. Events in the cardiac arrhythmia suppression trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol 18 (1991) 14-19
22. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327 (1992) 227-233
23. Flaker G.C., Blackshear J.L., McBride R., Kronmal R.A., Halperin J.L., and Hart R.G. The stroke prevention in atrial fibrillation investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 20 (1992) 527-532
24. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
25. Yamasaki N., Kitaoka H., Matsumura Y., Furuno T., Nishinaga M., and Doi Y. Heart failure in the elderly. Int Med 42 (2003) 383-388